Milan, Italy (August 27, 2025)
Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its attendance at 2025 Euretina Innovation Spotlight and Congress.
The event will be held September 3-8, 2025 in Paris, France. The co-founders Marco Ferroni, Chief Executive Officer, and Matteo Cereda, Clinical Advisor, will be attending the congress. The aims are the presentation of MgShell as emerging company in the retinal field in the exhibition area during the Innovation Spotlight, the consolidation of the current relationships and the establishment of the new ones with physicians and strategic partners, in order to implement MgShell Early Adopters Engagement Plan by starting preliminary conversations with vitreoretinal specialists.
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
